Investigating how a specific protein affects brain development in autism and related disorders
Cell type signaling specificity of the neurodevelopmental disease-associated DYRK1A kinase
This study is looking at how a protein called DYRK1A affects brain development and could be linked to autism and intellectual disabilities, with the hope that understanding this could help create better treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11092310 on NIH RePORTER |
What this research studies
This research explores the role of the DYRK1A protein in brain development, particularly in relation to autism spectrum disorders (ASD) and intellectual disabilities. By examining how mutations in DYRK1A influence calcium signaling in neural stem cells and their differentiation into neurons, the study aims to uncover the mechanisms behind neurodevelopmental diseases. The research involves both mouse models and human cells to understand the impact of DYRK1A on brain structure and function. Patients may benefit from insights that could lead to targeted therapies for ASD and related conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with autism spectrum disorders or related neurodevelopmental conditions linked to DYRK1A mutations.
Not a fit: Patients without any genetic mutations related to DYRK1A or those with unrelated neurodevelopmental disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for autism and other neurodevelopmental disorders.
How similar studies have performed: Previous research has shown promising results in understanding the role of DYRK1A in neurodevelopment, indicating that this approach has potential for significant findings.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Panagiotakos, Georgia — Icahn School of Medicine at Mount Sinai
- Study coordinator: Panagiotakos, Georgia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.